
Annual report 2023
added 03-21-2024
Landos Biopharma Market Cap 2011-2026 | LABP
As of April 30, 2026 Landos Biopharma has a market cap of $ 144 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Landos Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.1 M | 1.05 M | 129 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 129 M | 1.05 M | 59.3 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
6.69 M | $ 0.89 | - | $ 6.54 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
3.19 B | $ 22.2 | - | $ 3.68 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Edesa Biotech
EDSA
|
6.08 M | $ 15.9 | - | $ 50.8 M | ||
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | ||
|
Evogene Ltd.
EVGN
|
66.3 M | $ 0.76 | - | $ 27.9 M | ||
|
Exelixis
EXEL
|
11.7 B | $ 44.69 | - | $ 12.1 B | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Galapagos NV
GLPG
|
4.42 B | $ 27.86 | - | $ 2.69 B | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Grifols, S.A.
GRFS
|
8.42 B | $ 7.91 | - | $ 6.83 B | ||
|
Harmony Biosciences Holdings
HRMY
|
1.61 B | $ 31.05 | - | $ 1.79 B | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
ImmuCell Corporation
ICCC
|
58 M | $ 8.44 | - | $ 76.2 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 101.57 | - | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Immuron Limited
IMRN
|
348 M | $ 0.81 | 0.3 % | $ 9.47 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Incyte Corporation
INCY
|
19.5 B | $ 99.1 | - | $ 19.3 B | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
InMed Pharmaceuticals
INM
|
1.71 M | $ 0.7 | - | $ 1.71 M | ||
|
INmune Bio
INMB
|
28.2 M | $ 1.33 | - | $ 32.9 M | ||
|
Innoviva
INVA
|
1.62 B | $ 23.05 | - | $ 1.55 B | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Innate Pharma S.A.
IPHA
|
363 M | $ 1.48 | -0.67 % | $ 235 M | ||
|
Jaguar Health
JAGX
|
956 K | $ 7.88 | - | $ 18.4 M | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | ||
|
KalVista Pharmaceuticals
KALV
|
836 M | $ 26.67 | - | $ 1.44 B | ||
|
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | ||
|
Kamada Ltd.
KMDA
|
271 M | $ 8.11 | - | $ 260 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 2.98 | - | $ 4.91 M | ||
|
Krystal Biotech
KRYS
|
8.46 B | $ 259.95 | - | $ 7.52 B | ||
|
Kazia Therapeutics Limited
KZIA
|
132 M | $ 12.42 | - | $ 1.65 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
2.22 B | $ 224.86 | - | $ 4.11 B | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Liquidia Corporation
LQDA
|
2.95 B | $ 38.15 | - | $ 3.28 B | ||
|
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
467 M | $ 4.05 | - | $ 433 M | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M |